High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
- PMID: 18308250
- DOI: 10.1016/S1470-2045(08)70069-X
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
Abstract
Background: The current standard treatment for patients with high-risk neuroblastoma includes initial induction chemotherapy with a 21-day interval between induction treatments. We aimed to assess whether an intensive chemotherapy protocol that had a 10-day interval between treatments would improve event-free survival (EFS) in patients aged 1 year or over with high-risk neuroblastoma.
Methods: Between Oct 30, 1990, and March 18, 1999, patients with stage 4 neuroblastoma who had not received previous chemotherapy were enrolled from 29 centres in Europe. Patients were randomly assigned to rapid treatment (cisplatin [C], vincristine [O], carboplatin [J], etoposide [E], and cyclophosphamide [C], known as COJEC) or standard treatment (vincristine [O], cisplatin [P], etoposide [E], and cyclophosphamide [C], ie, OPEC, alternated with vincristine [O], carboplatin [J], etoposide [E], and cyclophosphamide [C], ie, OJEC). Both regimens used the same total cumulative doses of each drug (except vincristine), but the dose intensity of the rapid regimen was 1.8-times higher than that of the standard regimen. The standard regimen was given every 21 days if patients showed haematological recovery, whereas the rapid regimen was given every 10 days irrespective of haematological recovery. Response to chemotherapy was assessed according to the conventional International Neuroblastoma Response Criteria (INRC). In responders, surgical excision of the primary tumour was attempted, followed by myeloablation (with 200 mg/m2 of melphalan) and haemopoietic stem-cell rescue. Primary endpoints were 3-year, 5-year, and 10-year EFS. Data were analysed by intention to treat. This trial is registered on the clinical trials site of the US National Cancer Institute website, number NCT00365755, and also as EU-20592 and CCLG-NB-1990-11.
Findings: 262 patients, of median age 2.95 years (range 1.03-20.97), were randomly assigned-132 patients to standard and 130 patients to rapid treatment. 111 patients in the standard group and 109 patients in the rapid group completed chemotherapy. Chemotherapy doses were recorded for 123 patients in the standard group and 126 patients in the rapid group. 97 of 123 (79%) patients in the standard group and 84 of 126 (67%) patients in the rapid group received at least 90% of the scheduled chemotherapy, and the relative dose intensity was 1.94 compared with the standard regimen. 3-year EFS was 24.2% for patients in the standard group and 31.0% for those in the rapid group (hazard ratio [HR] 0.86 [95% CI 0.66-1.14], p=0.30. 5-year EFS was 18.2% in the standard group and 30.2% in the rapid group, representing a difference of 12.0% (1.8 to 22.3), p=0.022. 10-year EFS was 18.2% in the standard group and 27.1% in the rapid group, representing a difference of 8.9% (-1.2 to 19.0), p=0.085. Myeloablation was given a median of 55 days earlier in patients assigned rapid treatment than those assigned standard treatment. Infective complications (numbers of patients with febrile neutropenia and septicaemia, and if given, time on antibiotic and antifungal treatment) and time in hospital were greater with rapid treatment. Occurrence of fungal infection was the same in both regimens.
Interpretation: Dose intensity can be increased with a rapid induction regimen in patients with high-risk neuroblastoma. There was no significant difference in OS between the rapid and standard regimens at 5 years and 10 years. However, an increasing difference in EFS after 3 years suggests that the efficacy of the rapid regimen is better than the standard regimen. A rapid induction regimen enables myeloablation to be given much earlier, which might contribute to a better outcome.
Comment in
-
Chemotherapy for neuroblastoma: does it hit the target?Lancet Oncol. 2008 Mar;9(3):195-6. doi: 10.1016/S1470-2045(08)70046-9. Lancet Oncol. 2008. PMID: 18308243 Clinical Trial. No abstract available.
Similar articles
-
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259608 Clinical Trial.
-
Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.Cochrane Database Syst Rev. 2015 May 19;2015(5):CD010774. doi: 10.1002/14651858.CD010774.pub2. Cochrane Database Syst Rev. 2015. PMID: 25989478 Free PMC article. Review.
-
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
-
The evaluation of induction chemotherapy regimens for high-risk neuroblastoma in South African children.Pediatr Hematol Oncol. 2020 May;37(4):300-313. doi: 10.1080/08880018.2020.1717698. Epub 2020 Feb 19. Pediatr Hematol Oncol. 2020. PMID: 32075464
-
Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.Klin Padiatr. 2016 Apr;228(3):130-4. doi: 10.1055/s-0042-103158. Epub 2016 Apr 4. Klin Padiatr. 2016. PMID: 27043079 Review. English.
Cited by
-
The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches.Cancers (Basel). 2024 May 13;16(10):1863. doi: 10.3390/cancers16101863. Cancers (Basel). 2024. PMID: 38791942 Free PMC article. Review.
-
L-Glyceraldehyde Inhibits Neuroblastoma Cell Growth via a Multi-Modal Mechanism on Metabolism and Signaling.Cancers (Basel). 2024 Apr 25;16(9):1664. doi: 10.3390/cancers16091664. Cancers (Basel). 2024. PMID: 38730615 Free PMC article.
-
Association of the minimal cyclophosphamide equivalent dose and outcome of microdissection testicular sperm extraction in patients with persistent azoospermia after chemotherapy.F S Rep. 2023 Nov 14;5(1):95-101. doi: 10.1016/j.xfre.2023.11.005. eCollection 2024 Mar. F S Rep. 2023. PMID: 38524218 Free PMC article.
-
Prognostic factors for intermediate- or high-risk neuroblastomas in children in China.BMC Pediatr. 2023 Dec 6;23(1):617. doi: 10.1186/s12887-023-04258-w. BMC Pediatr. 2023. PMID: 38053080 Free PMC article.
-
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.Cancers (Basel). 2023 Oct 3;15(19):4837. doi: 10.3390/cancers15194837. Cancers (Basel). 2023. PMID: 37835531 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical